A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer .

Trial Profile

A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer .

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Enfortumab vedotin (Primary) ; Atezolizumab; Pembrolizumab
  • Indications Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Astellas Pharma Global Development
  • Most Recent Events

    • 20 Mar 2018 Trial design presented at the 33rd Congress of the European Association of Urology
    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
    • 06 Feb 2018 According to a Seattle Genetics media release, data will be presented at the American Society of Clinical Oncology 2018 Genitourinary Cancers Symposium (ASCO GU)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top